Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer

Abstract

microRNA-210 (miR-210), the master hypoxamir, is overexpressed and generally exhibits oncogenic properties in most human solid tumours, including colorectal cancer (CRC). However, the status of circulating miR-210 in CRC is still unknown. This study aims to assess the clinical significance of circulating miR-210 in CRC. Using (reverse transcription quantitative PCR) RT-qPCR analysis, we compared the expression levels of circulating miR-210 in serum of 268 CRC patients and 102 healthy controls, and found that serum miR-210 was significantly higher in CRC than in healthy controls (P < 0.001). The area under the receiver operating characteristic curve (AUC) of circulating miR-210 to detect CRC was 0.821, with a sensitivity of 74.6% and a specificity of 73.5%. The AUC of circulating miR-210 showed significantly higher detection capability than that of carcinoembryogenic antigen (P < 0.05). Kaplan-Meier analysis demonstrated that increased serum miR-210 level correlated with reduced overall survival (OS) and disease-free survival (DFS) (P = 0.008 and P = 0.008 respectively). Cox analysis indicated circulating miR-210 was an independent prognostic factor for OS and DFS. Taken together, our data suggested that circulating miR-210 could be a potential non-invasive marker for diagnosis and prognosis of CRC.

MiRNA-210: A Current Overview

“…Patients with breast cancer present increased levels of circulating miR-210; thus, circulating miR-210 may be a potential biomarker of tumor presence and therapeutic response in breast cancer (59). Moreover, hypoxia-inducible circulating miR-210 contributes to metastasis in colorectal cancer (CRC) (60), and it has recently been described as a potential non-invasive marker for diagnosis and prognosis of colorectal cancer (CRC) (61). Given the several different roles that miR-210 plays in numerous aspects of cellular function, it is also noteworthy to mention that hypoxia induces K562 and β-thalassemic erythroid progenitor cell differentiation, and this induction is at least in part mediated by miR-210, which, in turn, modulates a linkage between erythropoiesis and hypoxia (62).…”

miR-210 in Exosomes Derived from Macrophages under High Glucose Promotes Mouse Diabetic Obesity Pathogenesis by Suppressing NDUFA4 Expression

“…For instance, microRNA 144 could repress insulin signaling during type 2 diabetes mellitus development through suppressing the expression of Insulin Receptor Substrate 1 (IRS1) [26]. Currently, miR-210 has been reported to have significant contributions in various diseases including cardiovascular ischemic diseases [27,28], cancer [29,30], Graves' disease [31], and psoriasis [32]. Moreover, a group of miRNAs including miR-210 were differentially expressed in exosomes from obese adipose tissue macrophages [15].…”

Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR

“…Aberrant miRNA expression is associated with the occurrence of cancer in humans, such as colorectal cancer [8] and NSCLC [9]. Recently, miRNA (miR)-210, which is located on chromosome 11p15.5, was found to have multiple roles in various biological processes, such as angiogenesis and regulation of the immune system, by modulating cell proliferation, differentiation, degradation, and necrosis [10], and miR-210 was involved in the myocardial energy metabolism regulating the energy shift in cardiomyocytes during oxidative stress [11]. Deregulation of miR-210 may aberrantly activate oncogenes, deactivate tumor suppressor genes, inhibit DNA repair, and promote angiogenesis, ultimately accelerating the process of carcinogenesis, especially in a hypoxic environment [12].…”